Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171869327> ?p ?o ?g. }
- W2171869327 endingPage "671" @default.
- W2171869327 startingPage "667" @default.
- W2171869327 abstract "Purpose To retrospectively compare the outcome of upfront chemotherapy plus radiotherapy (CRT) and the outcome of the use of extended radiotherapy (RT) only for intracranial germinoma. Methods and Materials Of 81 patients with tissue-confirmed intracranial germinoma, 42 underwent CRT and 39 underwent RT only. For CRT, one to five cycles of upfront chemotherapy was followed by involved-field or extended-field RT, for which the dose was dependent on the M stage. For RT only, all 39 patients underwent craniospinal RT alone. The median follow-up was 68 months. Results The 5- and 10-year overall survival rate was 100% and 92.5% for RT alone and 92.9% and 92.9% for CRT, respectively. The 5-year recurrence-free survival rate was 100.0% for RT and 88.1% for CRT (p = 0.0279). No recurrences developed in patients given RT, but four relapses developed in patients who had received CRT—three in the brain and one in the spine. Only one patient achieved complete remission from salvage treatment. The proportion of patients requiring hormonal replacement was greater for patients who received RT than for those who had received CRT (p = 0.0106). Conclusions The results of our study have shown that the better quality of life provided by CRT was compensated for by the greater rate of relapse. The possible benefit of including the ventricles in involved-field RT after upfront chemotherapy, specifically for patients with initial negative seeding, should be addressed in a prospective study. To retrospectively compare the outcome of upfront chemotherapy plus radiotherapy (CRT) and the outcome of the use of extended radiotherapy (RT) only for intracranial germinoma. Of 81 patients with tissue-confirmed intracranial germinoma, 42 underwent CRT and 39 underwent RT only. For CRT, one to five cycles of upfront chemotherapy was followed by involved-field or extended-field RT, for which the dose was dependent on the M stage. For RT only, all 39 patients underwent craniospinal RT alone. The median follow-up was 68 months. The 5- and 10-year overall survival rate was 100% and 92.5% for RT alone and 92.9% and 92.9% for CRT, respectively. The 5-year recurrence-free survival rate was 100.0% for RT and 88.1% for CRT (p = 0.0279). No recurrences developed in patients given RT, but four relapses developed in patients who had received CRT—three in the brain and one in the spine. Only one patient achieved complete remission from salvage treatment. The proportion of patients requiring hormonal replacement was greater for patients who received RT than for those who had received CRT (p = 0.0106). The results of our study have shown that the better quality of life provided by CRT was compensated for by the greater rate of relapse. The possible benefit of including the ventricles in involved-field RT after upfront chemotherapy, specifically for patients with initial negative seeding, should be addressed in a prospective study." @default.
- W2171869327 created "2016-06-24" @default.
- W2171869327 creator A5008228126 @default.
- W2171869327 creator A5011410839 @default.
- W2171869327 creator A5014037323 @default.
- W2171869327 creator A5015058208 @default.
- W2171869327 creator A5021632136 @default.
- W2171869327 creator A5022442614 @default.
- W2171869327 creator A5024891671 @default.
- W2171869327 creator A5030157037 @default.
- W2171869327 creator A5043473358 @default.
- W2171869327 creator A5054187738 @default.
- W2171869327 creator A5057522489 @default.
- W2171869327 creator A5073690360 @default.
- W2171869327 creator A5077264803 @default.
- W2171869327 creator A5087839513 @default.
- W2171869327 date "2008-07-01" @default.
- W2171869327 modified "2023-10-15" @default.
- W2171869327 title "Upfront Chemotherapy and Involved-Field Radiotherapy Results in More Relapses Than Extended Radiotherapy for Intracranial Germinomas: Modification in Radiotherapy Volume Might Be Needed" @default.
- W2171869327 cites W1919098324 @default.
- W2171869327 cites W1965779893 @default.
- W2171869327 cites W1975572781 @default.
- W2171869327 cites W1985367724 @default.
- W2171869327 cites W1989004707 @default.
- W2171869327 cites W2015765584 @default.
- W2171869327 cites W2038315571 @default.
- W2171869327 cites W2075910427 @default.
- W2171869327 cites W2077128197 @default.
- W2171869327 cites W2077560844 @default.
- W2171869327 cites W2083024590 @default.
- W2171869327 cites W2110391100 @default.
- W2171869327 cites W2118076489 @default.
- W2171869327 cites W2127755477 @default.
- W2171869327 cites W2133520646 @default.
- W2171869327 cites W2138204078 @default.
- W2171869327 cites W2156823122 @default.
- W2171869327 cites W2407287700 @default.
- W2171869327 cites W4361868912 @default.
- W2171869327 doi "https://doi.org/10.1016/j.ijrobp.2008.01.061" @default.
- W2171869327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18514777" @default.
- W2171869327 hasPublicationYear "2008" @default.
- W2171869327 type Work @default.
- W2171869327 sameAs 2171869327 @default.
- W2171869327 citedByCount "43" @default.
- W2171869327 countsByYear W21718693272012 @default.
- W2171869327 countsByYear W21718693272013 @default.
- W2171869327 countsByYear W21718693272014 @default.
- W2171869327 countsByYear W21718693272015 @default.
- W2171869327 countsByYear W21718693272016 @default.
- W2171869327 countsByYear W21718693272017 @default.
- W2171869327 countsByYear W21718693272018 @default.
- W2171869327 countsByYear W21718693272019 @default.
- W2171869327 countsByYear W21718693272020 @default.
- W2171869327 countsByYear W21718693272021 @default.
- W2171869327 countsByYear W21718693272022 @default.
- W2171869327 countsByYear W21718693272023 @default.
- W2171869327 crossrefType "journal-article" @default.
- W2171869327 hasAuthorship W2171869327A5008228126 @default.
- W2171869327 hasAuthorship W2171869327A5011410839 @default.
- W2171869327 hasAuthorship W2171869327A5014037323 @default.
- W2171869327 hasAuthorship W2171869327A5015058208 @default.
- W2171869327 hasAuthorship W2171869327A5021632136 @default.
- W2171869327 hasAuthorship W2171869327A5022442614 @default.
- W2171869327 hasAuthorship W2171869327A5024891671 @default.
- W2171869327 hasAuthorship W2171869327A5030157037 @default.
- W2171869327 hasAuthorship W2171869327A5043473358 @default.
- W2171869327 hasAuthorship W2171869327A5054187738 @default.
- W2171869327 hasAuthorship W2171869327A5057522489 @default.
- W2171869327 hasAuthorship W2171869327A5073690360 @default.
- W2171869327 hasAuthorship W2171869327A5077264803 @default.
- W2171869327 hasAuthorship W2171869327A5087839513 @default.
- W2171869327 hasConcept C126838900 @default.
- W2171869327 hasConcept C141071460 @default.
- W2171869327 hasConcept C146357865 @default.
- W2171869327 hasConcept C151730666 @default.
- W2171869327 hasConcept C188816634 @default.
- W2171869327 hasConcept C2776694085 @default.
- W2171869327 hasConcept C2778895204 @default.
- W2171869327 hasConcept C509974204 @default.
- W2171869327 hasConcept C71924100 @default.
- W2171869327 hasConcept C86803240 @default.
- W2171869327 hasConceptScore W2171869327C126838900 @default.
- W2171869327 hasConceptScore W2171869327C141071460 @default.
- W2171869327 hasConceptScore W2171869327C146357865 @default.
- W2171869327 hasConceptScore W2171869327C151730666 @default.
- W2171869327 hasConceptScore W2171869327C188816634 @default.
- W2171869327 hasConceptScore W2171869327C2776694085 @default.
- W2171869327 hasConceptScore W2171869327C2778895204 @default.
- W2171869327 hasConceptScore W2171869327C509974204 @default.
- W2171869327 hasConceptScore W2171869327C71924100 @default.
- W2171869327 hasConceptScore W2171869327C86803240 @default.
- W2171869327 hasIssue "3" @default.
- W2171869327 hasLocation W21718693271 @default.
- W2171869327 hasLocation W21718693272 @default.
- W2171869327 hasOpenAccess W2171869327 @default.
- W2171869327 hasPrimaryLocation W21718693271 @default.
- W2171869327 hasRelatedWork W2089609493 @default.
- W2171869327 hasRelatedWork W2127755477 @default.